Review
Oncology
Laura Moliner, Bingnan Zhang, Giuseppe Lamberti, Andrea Ardizzoni, Lauren A. Byers, Raffaele Califano
Summary: The limited therapeutic options and poor prognosis for patients with relapsed small cell lung cancer are discussed in this review. Although there have been modest improvements in clinical outcomes with the introduction of immunotherapy in frontline treatment, treatment in the second-line setting has remained largely unchanged. The review also addresses current treatment options, recent advances in molecular biology, emerging therapeutic options, and potential strategies to improve clinical outcomes for these patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Esther Redin, Eva M. Garrido-Martin, Karmele Valencia, Miriam Redrado, Jose Luis Solorzano, Rafael Carias, Mirari Echepare, Francisco Exposito, Diego Serrano, Irene Ferrer, Angel Nunez-Buiza, Irati Garmendia, Juana M. Garcia-Pedrero, Alfonso Gurpide, Luis Paz-Ares, Katerina Politi, Luis M. Montuenga, Alfonso Calvo
Summary: YES1 was identified as a novel targetable oncogene driving SCLC maintenance and metastasis, and its overexpression was associated with poor prognosis.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Review
Cell Biology
Kate D. Sutherland, Abbie S. Ireland, Trudy G. Oliver
Summary: Small cell lung cancer (SCLC) is a rapidly growing, highly metastatic, and relatively immune-cold lung cancer subtype. It comprises multiple molecular subsets and exhibits tumor cell plasticity and phenotypic switching. This plasticity is associated with therapeutic resistance and immune-related gene expression.
GENES & DEVELOPMENT
(2022)
Article
Oncology
Walter Z. Wang, Alyssa Shulman, Joseph M. Amann, David P. Carbone, Philip N. Tsichlis
Summary: Small cell lung cancer (SCLC) is an aggressive tumor with poor understanding of its biology. Recent studies identified four distinct subsets of SCLC and revealed the importance of intratumoral heterogeneity in SCLC development and progression. These findings will inform the design of new therapeutic strategies.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ying Zhou, Yintao Zhang, Donghai Zhao, Xinyuan Yu, Xinyi Shen, Yuan Zhou, Shanshan Wang, Yunqing Qiu, Yuzong Chen, Feng Zhu
Summary: Target discovery is crucial for drug development, and assessing target druggability characteristics is essential. The therapeutic target database (TTD) has collected established characteristic categories to facilitate the discovery and validation of innovative drug targets.
NUCLEIC ACIDS RESEARCH
(2023)
Article
Oncology
Angana Biswas, Yetirajam Rajesh, Subhayan Das, Indranil Banerjee, Neelkamal Kapoor, Pralay Mitra, Mahitosh Mandal
Summary: Fusion genes result from chromosomal abnormalities, with ETV6-NTRK3 fusion protein activating pathways leading to cancer, highlighting the need for targeted therapy.
Article
Medicine, Research & Experimental
Juan Manuel Corral, Laura del Puerto-Nevado, Mabel Cedeno, Anxo Rio-Vilarino, Ignacio Mahillo-Fernandez, Carlos Galeano, Natalia Banos, Jesus Garcia-Foncillas, Manuel Domine, Arancha Cebrian
Summary: This study found that high levels of Gal-1 and PLR were associated with poorer prognosis in SCLC patients, supporting their utility as clinical prognostic biomarkers. Additionally, an in vivo model suggested that inhibition of Gal-1 may be a novel potential therapy for this disease with very poor prognosis.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Oncology
Joshua E. Reuss, Laura Gosa, Stephen Liu
Summary: ADCs combine the specificity of a monoclonal antibody with the cytotoxic effects of chemotherapy to facilitate targeted delivery of cytotoxic payloads to cancer cells. ADCs show promise in lung cancer treatment, with future applications looking increasingly relevant.
CLINICAL LUNG CANCER
(2021)
Review
Biotechnology & Applied Microbiology
Wei Ruan, Xiaoyi Yuan, Holger K. Eltzschig
Summary: The circadian clock plays a crucial role in integrating external environmental changes and internal physiology, providing temporal precision and robust adaptation to the environment. Disruption of circadian rhythms can lead to adverse health consequences, but there is still an underappreciation of how to take advantage of biological timing for health benefits. Promising progress in research and clinical applications should drive efforts towards a new era of circadian medicine.
NATURE REVIEWS DRUG DISCOVERY
(2021)
Article
Biochemistry & Molecular Biology
Tobias Friedrich, Francesca Ferrante, Leo Pioger, Andrea Nist, Thorsten Stiewe, Jean-Christophe Andrau, Marek Bartkuhn, Benedetto Daniele Giaimo, Tilman Borggrefe
Summary: The study investigates the role of transcription factor RBPJ in the Notch signaling pathway. It is found that RBPJ not only participates in the Notch co-activator complex, but also functions as a repressor, playing a crucial role in regulating Notch target genes.
NUCLEIC ACIDS RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Frank W. Pun, Ivan V. Ozerov, Alex Zhavoronkov
Summary: Disease modeling and target identification are crucial in drug discovery, and artificial intelligence is increasingly being used in this field. This article reviews recent advances in AI-driven target discovery and discusses the importance of striking a balance between novelty and confidence in target selection. It also highlights the validation of AI-identified targets through experiments and the potential pathways for further development.
TRENDS IN PHARMACOLOGICAL SCIENCES
(2023)
Review
Oncology
Borja Ruiz-Fernandez de Cordoba, Rafael Martinez-Monge, Fernando Lecanda
Summary: ENPP1 is frequently overexpressed in local relapses and tumor metastases, promoting an immunosuppressive tumor micro-environment and impairing immune response. Blocking ENPP1 could enhance immune remodeling and activate the STING pathway. Combination therapy with ENPP1 inhibitors and other modalities shows potential in improving antitumor-immune responses and clinical outcomes. This review summarizes the current state of the art and provides new perspectives for novel treatment strategies.
CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Alerie G. de la Fuente, Silvia Pelucchi, Jerome Mertens, Monica Di Luca, Daniela Mauceri, Elena Marcello
Summary: Ageing is the main risk factor for most primary neurodegenerative disorders, and protein misfolding and toxic protein accumulation are considered causative events. However, other biological pathways affected by brain ageing also contribute to pathogenesis. This article discusses the involvement of mechanisms controlling neuronal structure, gene expression, autophagy, cell metabolism, and neuroinflammation in the onset and progression of neurodegenerative disorders, and reviews therapeutic strategies aiming to normalize these pathways for increased brain resilience.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Oncology
Yujia Peng, Yiran Tao, Ya Zhang, Jiaxing Wang, Jinliang Yang, Yuxi Wang
Summary: CD25 is the alpha-chain of the heterotrimer IL-2 receptor, expressed on the surface of immune and non-immune cells with different frequencies. Its high expression in hematological malignancies and activated immune cells indicates its potential as a target for immunotherapy. The imbalanced ratio of effector T cells and regulatory T cells caused by Tregs infiltration in tumor microenvironment is associated with cancer progression. This paper summarizes the relationship between CD25 and tumors and discusses its important role in tumor therapy, as well as the recent progress of drugs targeting CD25.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Yvonne Gaertner, Lynn Bitar, Frauke Zipp, Christina Francisca Vogelaar
Summary: Interleukin-4 (IL-4) is a pleiotropic cytokine known for its role in type 2 immunity. Therapies targeting IL-4 have been developed for diseases like atopic dermatitis and asthma. However, IL-4 has also shown beneficial effects in experimental stroke, spinal cord injury, and multiple sclerosis. Efforts are being made to modify the IL-4 pathway and target it to specific tissues for therapeutic purposes. This review discusses the different activities of IL-4 and potential therapeutic strategies.
PHARMACOLOGY & THERAPEUTICS
(2023)
